Market Overview

UPDATE: JP Morgan Raises PT to $31 on Pfizer Following Q4 Results, Guidance

Share:
Related PFE
Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback
3 Highlights From A Spark Therapeutics Fireside Chat
Sabal Trust CO Buys United Parcel Service Inc, Bristol-Myers Squibb Company, Hanesbrands Inc, ... (GuruFocus)

JP Morgan maintained Pfizer, Inc. (NYSE: PFE) with an Overweight and raised the price target from $29.00 to $31.00.

JP Morgan said, "While there were no major surprises in the guidance, management did confirm that they expect share repurchase to reach mid-teens billions of dollars range this year. More importantly, management's comments on the call reinforced our view that a larger split-up of the company remains a real possibility longer-term, something we believe would be a clear upside event for Pfizer shares. Despite the move the stock has had, we continue to see a number of drivers for further upside ranging from new product flow, to additional capital return and accretive bolt-on acquisitions."

Pfizer closed at $27.70 on Tuesday.

Latest Ratings for PFE

DateFirmActionFromTo
Sep 2017Morgan StanleyUpgradesEqual-WeightOverweight
Aug 2017BMO CapitalUpgradesMarket PerformOutperform
Jul 2017Credit SuisseMaintainsNeutral

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...